LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability
Abstract
Data di Pubblicazione:
2007
Citazione:
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability / Frassoldati, A; Guarneri, Valentina; Cagossi, K.; Bottini, A; Cavanna, L; Jovic, Gordana; Piacentini, Federico; Oliva, C; Conte, Pierfranco. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - STAMPA. - 10s, S1 (abstract 2087):(2007), pp. s114-s114. ( 30th Annual San Antonio Breast Cancer Symposium San Antonio, TX December 13-16, 2007).
Abstract:
The crosstalk between hormone- and EGFR-family pathways is considered a possible cause of hormone-resistance. To evaluate the effects of a combined blockade of these two pathways, we activated an international multicentre phase IIb double blind randomized trial in neoadjuvant setting.
Tipologia CRIS:
Abstract in Rivista
Keywords:
lapatinib; letrozole; preoperative therapy; EGFR
Elenco autori:
Frassoldati, A; Guarneri, Valentina; Cagossi, K.; Bottini, A; Cavanna, L; Jovic, Gordana; Piacentini, Federico; Oliva, C; Conte, Pierfranco
Link alla scheda completa:
Titolo del libro:
Breast Cancer research and treatment, Special Issue 30th Annual San Antonio Breast Cancer Symposium
Pubblicato in: